FDA completes its review of Lannett’s IND for biosimilar insulin glargine

by | Jan 21, 2022

Lannett announced that the FDA has completed its review of the Investigational New Drug Application for biosimilar insulin glargine.  Lannett plans to complete the clinical trials by early 2023, with a potential launch in early 2024.

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News